Trial Profile
A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 11 Nov 2021 Planned End Date changed from 31 Jan 2021 to 31 Jan 2023.
- 11 Nov 2021 Planned primary completion date changed from 31 Jan 2021 to 31 Jan 2022.